Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: Critical evaluation of an association with HLA-DR3

Tissue Antigens

Volumn 64, Issue 5, 2004, Pages 575-580

  Price, Patricia ^a,b   Santoso, L ^a   Mastaglia, F ^a   Garlepp, M ^c   Kok, C C ^d   Allcock, R ^a,b   Laing, N ^a,e  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Ancestral haplotype; Inclusion body myositis; MHC; Microsatellite; Single nucleotide polymorphism

Indexed keywords

HLA A1 ANTIGEN; HLA A3 ANTIGEN; HLA A30 ANTIGEN; HLA ANTIGEN; HLA B18 ANTIGEN; HLA B35 ANTIGEN; HLA B8 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DR3 ANTIGEN; HLA DRB3 ANTIGEN; HOX PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCUS; GENE MAPPING; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HUMAN; HUMAN TISSUE; INCLUSION BODY MYOSITIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MUSCLE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HLA-B8 ANTIGEN; HLA-DR3 ANTIGEN; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMBRANE GLYCOPROTEINS; MYOSITIS, INCLUSION BODY;

MARTES PENNANTI;

EID: 8144225858     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2004.00310.x     Document Type: Article

References (20)

1. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991: 325: 1487-98.
2. Phillips BA, Zilko PJ, Mastaglia FL. Muscle prevalence of sporadic inclusion body myositis in Western Australia. Nerve 2000: 23: 970-2.
3. Askanas V, Engel WK, Yang CC, Alvarez RB, Lee VM, Wisniewski T. Light and electron microscopic immunolocalization of presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy. Am J Pathol 1998: 152: 889-95.
4. Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003: 27: 407-25.
5. Bender A, Behrens L, Engel AG, Hohlfeld R. T-cell heterogeneity in muscle lesions of inclusion body myositis. J Neuroimmunol 1998: 84: 86-91.
6. Sekul EA, Dalakas MC. Inclusion body myositis: new concepts. Semin Neurol 1993: 13: 256-63.
7. Koffman BM, Sivakumar K, Simonis T et al. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J Neuroimmunol 1998: 84: 139-42.
8. Garlepp MJ, Laing B, Zilko PJ et al. HLA associations with inclusion body myositis. Clin Exp Immunol 1994: 98: 40-5.
9. Kok CC, Croager EJ, Witt CS et al. Mapping of a candidate region for susceptibility to inclusion body myositis in the human major histocompatibility complex. Immunogenetics 1999: 49: 508-16.
10. Price P, Witt C, Allcock R et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 1999: 167: 257-74.
11. Cheong KY, Allcock RJ, Eerligh P, Christiansen F, Allcock R, Price P. Localization of central MHC genes influencing type I diabetes. Hum Immunol 2001: 62: 1363-70.
12. Ishihara M, Ohno S, Mizuki N et al. Genetic polymorphisms of the major histocompatibility complex-encoded antigen-processing genes TAP and LMP in sarcoidosis. Hum Immunol 1996: 45: 105-10.
13. Stammers M, Rowen L, Rhodes D, Trowsdale J, Beck S. BTL-II: a polymorphic locus with homology to the butyrophilin gene family, located at the border of the major histocompatibility complex class II and class III regions in human and mouse. Immunogenetics 2000: 51: 373-82.
14. Allcock RJN, Christiansen FT, Price P. The central MHC gene IKBL carries a structural polymorphism that is associated with HLA-A3,B7,DR15. Immunogenetics 1999: 49: 660-5.
15. Zanelli E, Jones G, Pascual M et al. The telomeric part of the HLA region predisposes to rheumatoid arthritis independently of the class II loci. Hum Immunol 2001: 62: 75-84.
16. Stern D, Du Yan S, Fang Yan S, Schmidt MA. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 2002: 54: 1615-25.
17. Chen QY, Nadell D, Zhang XY et al. The human leukocyte antigen HLA DRB3*020/DQA1*0501 haplotype is associated with Graves' disease in African Americans. J Clin Endocrinol Metab 2000: 85: 1545-9.
18. Smikie MF, Pascoe RW, Barton E et al. HLA-DRB3*0101 is associated with Graves' disease in Jamaicans. Clin Endocrinol 2001: 55: 805-8.
19. Leong KG, Hu X, Li L et al. Activated Notch4 inhibits angiogenesis: role of beta 1-integrin activation. Mol Cell Biol 2002: 22: 2830-41.
20. NA. The MHC sequencing consortium: complete sequence and gene map of a human major histocompatibility complex. Nature 1999: 401: 921-3.